About Regor
Regor is a company based in Boston (United States) founded in 2018 was acquired by Roche in September 2024. Regor has raised $90 million across 2 funding rounds from investors including Roche, Qilu Pharmaceutical Group and Lilly Asia Ventures. Regor offers products and services including GDC-4198, RGT-075, RGT-419B, and RGT-587. Regor operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Regor Therapeutics Group
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Regor
Regor offers a comprehensive portfolio of products and services, including GDC-4198, RGT-075, RGT-419B, and RGT-587.
Next-generation inhibitor for breast cancer treatment in clinical trials
Oral small molecule for obesity and type 2 diabetes management
CDK inhibitor for advanced breast cancer patients
Next-gen treatment for breast cancer in phase trials
People of Regor
Unlock access to complete
Unlock access to complete
Funding Insights of Regor
Regor has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $90 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Regor
Regor has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Qilu Pharmaceutical Group and Lilly Asia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mid-market companies are targeted for investment by Loayal Valley Capital.
|
Locked | Locked | Locked | |
|
TF Capital is engaged in biotech investment and strategic support.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Regor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regor
Investment portfolio details for Regor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Regor
Detailed financials for Regor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regor Comparisons
Peer comparison for Regor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Regor
Regor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Regor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regor
Complete news archive for Regor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regor
Regor was founded in 2018.
Regor is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Regor is a funded company, having raised a total of $90M across 2 funding rounds to date.
Regor was founded in 2018 in Boston, United States, within the biotechnology sector. Therapeutics targeting oncology, autoimmune, and metabolic diseases are developed. A multi-disciplinary computational platform is employed, integrating structural biology, biopharmaceutics, PKPD modeling, and bioinformatics. Drug discovery processes are supported from target identification and lead optimization through to clinical proof of concept, with operations based in the United States.
Regor's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Regor offers GDC-4198, RGT-075, RGT-419B, and RGT-587.
Regor has 7 investors. Key investors include Roche, Qilu Pharmaceutical Group, Lilly Asia Ventures, Loayal Valley Capital, and LanTing Capital.